Abstract
Protect brand revenues with a multi-tiered counter-generics strategy:
Generic drugs now account for more than 60% of all prescriptions filled in the
US, and more than $60 billion worth of drugs face US patent expiration by 2011.
Use this report to build a counter-generics strategy that includes long-term,
R&D-based lifecycle planning (such as new formulations and next-generation
drugs) as well as frontline tactics (such as litigation and counter-promotion)
-- and understand how companies launch authorized generics and attempt OTC
switches
Explore primary data for a comprehensive look at current counter-generics
defense:
- Investigate strategies, investments and results for seven brands
- Benchmark your efforts against timelines, investment levels, and
past-and-future use of critical lifecycle management and counter-generics
options:
- New formulation launches
- Defensive pricing changes
- Counter-promotion
- Approval for new indications
- Next-generation product launches
- Patent litigation
- Authorized generics negotiations
- Launches through generics subsidiaries
- Pediatric trials and six-month exclusivity
- OTC switching
- Compare headcounts dedicated to counter-generics preparation over the life
of a brand
| 
View Cart
